Find Funding Opportunities

NIH Extramural Response to Natural Disasters and Other Emergencies

In emergency situations, the NIH’s immediate concern is for the health and safety of people and animals in the programs we oversee.  Visit the NIH Extramural Response to Natural Disasters and Other Emergencies web page for biomedical research community resources, including NIH Guide Notices and other information of particular relevance to investigators and their institutions, links to web pages listing NIH’s response to certain major events (past and present); and links to similar web sites from other Federal agencies.

 COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements

All NINDS-related notices of funding opportunities (NOFOs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed. Search the Closed Opportunities tab to find expired opportunities. Search the Notices tab to find all Notices.

Learn more about award types and program directors and managers.

NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!

For more focused results add quotes to indicate parameters. Example format: "search term".

Displaying 1051 - 1060 of 1391 Notices
Notice of NIH Participation in the National Robotics Initiative (NRI)
Expiration Date: Saturday, January 1, 2028
NOFO Number: NOT-EB-11-006
Friday, June 24, 2011
Notice Type: NOT
Notice NIH Participation the National Robotics Initiative NRI) Notice Number: NOT-EB-11-006 Update: following update relating this announcement been issued: September 21, 2012 - Updates the NRI - Notice updates supersedes previous Guide Notice,NOT-EB-11-006. Notice NOT-EB-12-006. Key Dates Release Date: June 24, 2011 Issued National Institutes Health NIH)      National Institute Biomedical Imaging Bioengineering NIBIB)      National Institute Aging NIA)      Eunice Kennedy Shriver National Institute Child Health Human Development NICHD)     National Institute Nursing Research NINR)     National Institute Neurological Disorders Stroke NINDS)     National Center Research Resources NCRR) National Science Foundation NSF) National Aeronautics Space Administration NASA) U.S. Department Agriculture USDA) Purpose purpose this Notice to announce the NIH collaborating a multi-agency funding opportunity, National Robotics Initiative NRI) http://www.nsf.gov/nri), whose goal to accelerate development use robots the United States work beside, cooperatively with, people http://www.nsf.gov/publications/pub_summ.jsp?WT.z_pims_id=503641&ods_ke…; Innovative robotics research applications emphasizing realization such co-robots acting direct support a human supported multiple agencies the federal government including National Institutes Health NIH), National Science Foundation NSF), National Aeronautics Space Administration NASA), the U.S. Department Agriculture USDA). initiative facilitate development the next generation robotics, particularly co-robotics, encourage existing new communities focus innovative application areas. Collaboration between academic, industry, non-profit other organizations strongly encouraged establish better linkages between fundamental science technology development use.  NIH areas interest include, are limited to, robotics home care; personalized care special needs populations robotic wellness/health promotion; robot-assisted recovery; rehabilitation behavioral therapy; surgical interventional robots; high-throughput robotic technologies. Award Information Award sizes NIH funded research projects expected range approximately 100,000 250,000 per year direct costs, durations one five years.  award exceed 250,000 per year direct costs. Estimated program budget, number awards average award size duration subject the availability funds.  Determination awards based three criteria: 1) availability funds, 2) program priorities, 3) scientific merit. Subsequent grant administration procedures be accordance the policies the awarding Institute. Application Preparation Submission Instructions Applications submitted response this program announcement/solicitation should prepared submitted accordance the general guidelines contained the NSF Grant Proposal Guide GPG).  Applications must submitted the NSF, to NIH.  complete text the GPG available electronically the NSF Web Site at: http://nsf.gov/publications/pub_summ.jsp?ods_key=gpg.   Applicants reminded identify NSF program announcement number the program announcement block the NSF Cover Sheet Proposal the National Science Foundation.  Compliance this announcement critical determining relevant application processing guidelines.  Failure submit information delay processing. Budgetary Information Cost sharing not required applications submitted this funding opportunity. Budgets should include travel funds the PD/PI team members attend annual NRI Principal Investigators' meeting. NIH Process goal this activity to involve multiple agencies using application one review. meet NIH requirements, those applications are identified potential funding participating NIH Institutes Centers ICs), applicant organization be required submit R01application an NIH-approved format directly the Center Scientific Review http://www.csr.nih.gov/) the NIH.  PD/PIs invited submit NIH receive further information submission procedures the NIH. NIH application not allowed increase proposed budget change scientific content the application the converted submission the NIH. The summary statement be presented the involved IC's National Advisory Council the second level review. Subsequent the Council review, NIH ICs make funding determinations selected awards be made. Grant administration procedures NIH awardees, including those related New Early Stage Investigators http://grants.nih.gov/grants/new_investigators/) be accordance the policies NIH. Please note applications be submitted review the NSF November 3, 2011. Notification applications selected potential funding the participating NIH ICs be received the end March, 2012.  converted submission NIH be due April 11, 2012, will an extremely short conversion time.  applicant organization want work closely their Sponsored Programs Office assure timely submission during narrow submission window. earliest project start date be July 1, 2012. Inquiries Written telephone inquiries encouraged.  NIH Program contacts listed below. Please the NSF program announcement names contact information each the participating NSF Directorates http://www.nsf.gov/nri. John W. Haller, Ph.D., National Institute Biomedical Imaging Bioengineering 6707 Democracy Blvd., Bethesda, MD 20892 Telephone: 301.451.4780;  Fax: 301.480.4973 Email: hallerj@mail.nih.gov; http://www.nibib.nih.gov Lyndon Joseph, Ph.D Health Scientist Administrator Division Geriatrics Clinical Gerontology National Institute Aging, NIH, DHHS 7201 Wisconsin Avenue, Suite 3C307 Bethesda, MD 20892-9205 Telephone: 301-496-6926 Fax: 301-402-1784 Email: Josephlj@nia.nih.gov       www.nia.nih.gov Louis Quatrano, Ph. D. Program Director, BSRE, NCMRR Eunice Kennedy Shriver National Institute Child Health Human Development National Institutes Health 6100 Executive Blvd, Rm 2A03, MSC 7510, Bethesda, MD 20892-7510 Rockville, MD 20852 express/courier service) Office:  301-402-4221 Fax:  301-402-0832 Email: quatranl@mail.nih.gov   Paul A. Cotton, PhD, RD, Program Director National Institute Nursing Research NINR) 6701 Democracy Blvd, Ste. 710 Democracy Plaza Bethesda, MD 20892-4870 Courier zip: 20817) Phone: 301.402.6423 Fax:      301.451.5647 Email: Paul.Cotton@nih.gov;    http://www.ninr.nih.gov/ Daofen Chen,  Ph.D. Program Director Systems Cognitive Neuroscience National Institute Neurological Disorders Stroke NINDS/NIH) NIH Neuroscience Center, Room 2176 6001 Executive Boulevard Bethesda, MD 20892-9523 (FEDEX 20852) Phone: 301) 496-9964, FAX: 301) 402-1501 Email: daofen.chen@nih.gov  
Notice of Clarification for RFA-DK-11-010: Clinical Trial Planning Grants in Type 1 Diabetes (R34)

Expiration Date: Saturday, January 1, 2028
NOFO Number: NOT-DK-11-012
Thursday, June 23, 2011
Notice Type: NOT
Notice Clarification RFA-DK-11-010: Clinical Trial Planning Grants Type 1 Diabetes R34) Notice Number: NOT-DK-11-012 Key Dates Release Date: June 23, 2011 Issued National Institute Diabetes Digestive Kidney Diseases NIDDK) National Heart, Lung, Blood Institute NHLBI) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Neurological Disorders Stroke NINDS)) Purpose purpose this Notice to clarify funding applications submitted RFA-DK11-010: Clinical Trial Planning Grants Type Diabetes R34) of  future clinical trials may conducted awardees an R34 Clinical Trial Planning Grant under FOA. OLD LANGUAGE Section Funding Opportunity Description) FOA utilize NIH Clinical Trial Planning Grant R34) support development clinical trials individuals type 1 diabetes. Contingent the merit the proposed trials the availability funds, NIH anticipates funding up three full scale trials the funded R34 planning grants.  During early funding period the R34 grant, investigators have opportunity revise protocol based considerations raised peer review.  NIH then seek external input will guide priorities the support a limited number full clinical trials selected the funded R34 protocols.  Those clinical trials be conducted collaboration a single data coordinating center will awarded through future FOA. data coordinating center work R34 awardees finalize protocol budget, complete administrative tasks recruit clinical sites.  data coordinating center award provide support the conduct the selected trials.  Clinical trials developed under R34 grants are prioritized implementation through data coordinating center be appropriate support through funding sources mechanisms. NIDDK amending  Section I, paragraph four add following: Depending the merit cost the clinical trials proposed the applications, only single award be made, should most meritorious application a clinical trial utilize available funds. NIDDK also deleting following sentences: Those clinical trials be conducted collaboration a single data coordinating center will awarded through future FOA. data coordinating center work R34 awardees finalize protocol budget, complete administrative tasks recruit clinical sites.  data coordinating center award provide support the conduct the selected trials.   NIDDK adding sentence:  trials be funded through future FOA. NEW LANGUAGE Section I. Funding Opportunity Description, paragraph four FOA utilize NIH Clinical Trial Planning Grant R34) support development clinical trials individuals type 1 diabetes. Contingent the merit the proposed trials the availability funds, NIH anticipates funding up three full scale trials the funded R34 planning grants. Depending the merit cost the clinical trials proposed the applications, only single award be made, should most meritorious application a clinical trial utilize available funds. During early funding period the R34 grant, investigators have opportunity revise protocol based considerations raised peer review.  NIH then seek external input will guide priorities the support a limited number full clinical trials selected the funded R34 protocols.  trials be funded through future FOA. Clinical trials developed under R34 grants are prioritized implementation be appropriate support through funding sources mechanisms. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Teresa Jones, M.D. National Institute Diabetes Digestive Kidney Diseases 6707 Democracy Boulevard Bethesda, MD 20892 Telephone: 301) 435-2996 FAX: 301) 480-3503 E-mail: jonester@mail.nih.gov
Extension of Expiration Dates for PA-08-246 (R01) and PA-08-247 (R21): Chronic Fatigue Syndrome: Pathophysiology and Treatment


Expiration Date: Saturday, January 1, 2028
NOFO Number: NOT-OD-11-083
Friday, June 10, 2011
Notice Type: NOT
Extension Expiration Dates PA-08-246 R01) PA-08-247 R21):  Chronic Fatigue Syndrome: Pathophysiology Treatment Notice Number: NOT-OD-11-083 Key Dates Release Date: June 10, 2011 Issued Office Research Women’s Health ORWH) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Environmental Health Sciences NIEHS) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Center Complementary Alternative Medicine NCCAM) National Center Research Resources NCRR) Office Dietary Supplements ODS) Purpose Notice extends expiration dates the Funding Opportunity Announcements FOA) PA-08-246 R01) PA-08-247 R21), Chronic Fatigue Syndrome: Pathophysiology Treatment.   new expiration date both FOAs January 8, 2012.  updated list Institute Center Science/Research contacts be posted the Trans-NIH ME/CFS Research Working Group website http://orwh.od.nih.gov/CSF%202011/resources.htm).  other aspects these FOAs remain unchanged. Inquiries Please direct inquiries to: Dennis F. Mangan, Ph.D. Chair, Trans-NIH ME/CFS Research Working Group Senior Research Advisor Office Research Women's Health, OD National Institutes Health 6707 Democracy Blvd., Suite 400 Bethesda, MD  20892-5484 Telephone:  301 496-9006 FAX:  301 402-1798 Email:  dennis.mangan@nih.gov
Notice of Intent to Publish a Request for Applications for Stroke Prevention/Intervention Research Program (SPIRP) (U54)
Expiration Date: Saturday, January 1, 2028
NOFO Number: NOT-NS-11-017
Tuesday, June 7, 2011
Notice Type: NOT
Notice Intent Publish Request Applications Stroke Prevention/Intervention Research Program SPIRP) U54) Notice Number: NOT-NS-11-017 Key Dates Release Date: June 7, 2011 Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS) intends promote new initiative publishing Funding Opportunity Announcement FOA) solicit applications Stroke Prevention/Intervention Research Programs SPIRP); goal be develop interventions research have potential reduce stroke disparities minority communities through effective and culturally appropriate stroke prevention/intervention programs. Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects.  FOA expected be published Fall 2011 an expected receipt date Winter 2012. FOA utilize U54 activity code. U54 mechanism a solicited, multi-component award mechanism which substantial NIH scientific and/or programmatic involvement anticipated project completion.  Details the planned FOA provided below. Research Initiative Details Stroke the fourth leading cause death a leading cause long-term disability.  Stroke disparities a major public health problem the United States due the excess burden disease, excess mortality, worse outcome minority populations.  address these, innovative effective strategies directly reduce incidence, morbidity, mortality stroke racial/ethnic minority communities are within programmatic priority NINDS of interest. initiative directly responds the recommendations the NINDS Advisory Panel Health Disparities http://www.ninds.nih.gov/about_ninds/plans/NINDS_health_disparities_rpt…(pdf, 196 KB)) the Health Human Services plan addressing health disparities http://www.minorityhealth.hhs.gov/npa/files/Plans/HHS/HHS_Plan_complete…).  the purposes this announcement, stroke defined broadly may address ischemic hemorrhagic stroke disparities minority communities.  SPIRP application program) must contain least stroke prevention/intervention project up 3 additional projects directly related stroke disparities. additional projects range basic science through outcomes research.  projects should aim identify, monitor target biologic, environmental, social, healthcare system factors confer stroke its treatment disproportionately adversely underserved minority populations. nbsp;We anticipate trans-disciplinary multi-disciplinary teams be used implement SPIRP projects.  Projects also tools such community engagement, decision analysis, economic analysis, patient-centered outcomes enhance overall SPIRP. nbsp;Applications have cores are directly related the administration, training, scientific function the program. overall aims this initiative are: 1) develop effective evidence-based interventions prevention strategies designed decrease identified disparities stroke the potential be scaled-up regional national implementation; 2) support stroke disparities research projects are most likely targets next generation prevention/intervention programs that significantly further knowledge the research gaps stroke disparities; 3) provide formal, quality training junior investigators key stakeholders the implementation the prevention/intervention project.  Importantly, only prevention/intervention projects are culturally appropriate be considered.  Therefore, applicant should discuss methodology used address important element may include theoretical constructs population group specific socio-cultural bio-behavioral variables including health beliefs practices.    APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: Salina Waddy, MD Program Director National Institute Neurological Disorders Stroke NINDS) 6001 Executive Boulevard, Room 2153  Bethesda, Maryland 20892 Phone: 301- 496-9135 FAX: 301) 402-1501 Email: waddysp@mail.nih.gov Website: http://www.ninds.nih.gov
Extension of Expiration Date for NIAID Funding Opportunity Announcement: Investigations on Primary Immunodeficiency Diseases (R01) PAR-08-206
Expiration Date: Saturday, January 1, 2028
NOFO Number: NOT-AI-11-047
Wednesday, May 25, 2011
Notice Type: NOT
Extension Expiration Date NIAID Funding Opportunity Announcement: Investigations Primary Immunodeficiency Diseases R01) PAR-08-206 Notice Number: NOT-AI-11-047 Key Dates Release Date: 25, 2011 Issued National Institute Allergy Infectious Diseases NIAID) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Neurological Disorders Stroke NINDS) Purpose Notice extends expiration date the Funding Opportunity Announcement:  Investigations Primary Immunodeficiency Diseases R01) PAR-08-206 http://grants.nih.gov/grants/guide/pa-files/PAR-08-206.html) one receipt date.  a result, FOA being extended September 8, 2011 January 8, 2012. other aspects this FOA remain unchanged. Inquiries contacts FOA any inquires.
Request for Information: Whole Genome Sequencing, Data Analysis, Storage and Annotation

Expiration Date: Saturday, January 1, 2028
NOFO Number: NOT-NS-11-015
Wednesday, May 11, 2011
Notice Type: NOT
Request Information: Whole Genome Sequencing, Data Analysis, Storage Annotation Notice Number:  NOT- NS-11-015   Key Dates Release Date:     11, 2011 Response Date:  30, 2011    Issued National Institute Neurological Disorders Stroke NINDS) Purpose is time sensitive Request Information RFI) issued the National Institute Neurological Disorders Stroke NINDS).  purpose the RFI to solicit information the research needs the NINDS community whole genome sequencing services accompanying data storage, analysis annotation services.  responses the RFI be collected evaluated Institute staff assess best meet current future needs whole genome sequencing it relates neurologic disease. Background Rapid significant changes technology continue advance our understanding human biology disease technological applications ranging single molecule whole genome approaches.  of technologies, massively parallel sequencing Next Generation Sequencing NGS) revolutionized our ability identify rare variants as yet unidentified Mendelian mutations related disease.  Although is clear NGS technology eventually dominate genomic research field, technological developments resulting reductions cost rapid increases sequencing speed improved accuracy.  reality these advancements sequencing technology enables re-sequencing the whole human genome be achieved within weeks instead months years unprecedented accuracy.  NGS technologies leading new strategies the understanding monogenic Mendelian diseases allowing identification causative mutations disorders were amenable linkage-based positional cloning Lupski J.R. et al., 2010]. Although cost availability services play role determining NGS approach exome verses whole genome), understanding underlying complexity the disease phenotype a key selection eventual success identifying causative mutation.  Since technologic advancements NGS been rapid, volume complexity the information captured through NGS challenges storage processing capabilities many laboratories institutions.  all roadblocks accessing NGS services processing NGS data removed, perhaps greatest challenge be analysis annotation data effectively differentiate between many rare benign variants detected novel genomic techniques disease causing mutations. RFI meant solicit information extramural research investigators regarding type availability projects can advanced through whole genome sequencing services.  RFI also solicits information institutional capabilities sequence storage, data analysis annotation.  Responses this RFI be reviewed NINDS staff will help inform complement assessment current future whole genome sequencing needs. RFI for planning purposes only, should be construed a solicitation applications proposals and/or an obligation any on part the United States Federal Government. Sequencing Services 1.  Describe whole genome sequencing services available planned your institution. 2.  Describe composition your research cohort e.g. small large families, population based) will utilize whole genome sequencing. 3.  Indicate you anticipate whole genome sequencing contribute your field research. 4.  Provide rationale choosing whole genome sequencing over whole exome sequencing. 5.  you plan utilize whole genome sequencing, many samples you sequence within next 12 months? will samples chosen? 6.  Outline plans your laboratory institution regarding storage capacity raw data generated whole genome sequencing. 7.  are plans your laboratory institution regarding analytical support sequence assembly, variant identification annotation? 8. Provide perspective the constraints regarding public sharing genomic sequences associated phenotype your research cohort. General Information 1.  Please identify nature your interest the area whole genome sequencing services i.e. you biomedical clinical researcher, member an advocacy community group, other?). 2.  you a member a particular advocacy professional organization, please indicate name the organization. 3.  Please indicate main area research interest. 4.  name 5.  email address * Note: of preceding fields optional. Proprietary, classified, confidential, sensitive information should be included your response.  Responses Responses must submitted electronically using web-based form http://www.ninds.nih.gov/funding/areas/neurodegeneration/RFI-for-Whole-… will accepted through 30, 2011.  Replies individual questions optional, the site permit anonymous responses. information provided be analyzed may appear various reports. Inquiries Please direct inquiries to: Margaret Sutherland, PhD Program Director, Neurodegeneration Cluster NINDS / NIH 6001 Executive Blvd., Rm 2222 Bethesda, MD 20892 Phone: 301-496-5680 Fax: 301-480-1080 E-mail: sutherlandm@ninds.nih.gov 
Withdrawal of NINDS participation in PA-10-056, Mentored Research Scientist Development Award (Parent K01)
Expiration Date: Saturday, January 1, 2028
NOFO Number: NOT-NS-11-013
Monday, April 11, 2011
Notice Type: NOT
NINDS no longer utilize Mentored Research Scientist Development Award Parent K01; PA-11-190) support scientists re-entering research Notice Number: NOT-NS-11-013 Key Dates Release Date: April 11, 2011   Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to notify potential applicants for PA-11-190 formerly PA-10-056, is expiring 8, 2011), NINDS no longer accept new ReEntry K01 submissions.  NINDS accept resubmission applications only cycles II July 12) III November 12) 2011.  the future, NINDS use K01 support mechanism exclusively the purpose promoting diversity neuroscience research through PAR-09-065, is still active. Candidates interested support re-entry Neurological research should the NINDS Re-Entry supplement program an alternate opportunity: http://www.ninds.nih.gov/funding/areas/office_of_minority_health_and_re…. Inquiries Please direct inquiries to: Michelle Jones-London, Ph.D. Program Director Office Minority Health Research National Institute Neurological Disorders Stroke 6001 Executive Blvd NSC, Suite 2149, MSC 9535 Bethesda, MD 20892-9535 301-451-7966; Fax 301-594-5929 jonesmiche@ninds.nih.gov
Notice of Intent to Publish a Request for Applications for a Spinal Muscular Atrophy (SMA) Biomarker Study (U01) and Convene a Related Workshop
Expiration Date: Saturday, January 1, 2028
NOFO Number: NOT-NS-11-012
Friday, April 8, 2011
Notice Type: NOT
Notice Intent Publish Request Applications a Spinal Muscular Atrophy SMA) Biomarker Study U01) Convene Related Workshop Notice Number: NOT-NS-11-012 Key Dates Release Date: April 8, 2011 Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS) intends promote new initiative publishing Funding Opportunity Announcement FOA) solicit applications clinical research studies will accelerate augment validation biomarkers Spinal Muscular Atrophy SMA). Notice being provided allow potential applicants sufficient time develop responsive protocols necessary collaborations. FOA expected be published the NIH Guide Grants Contracts late spring/early summer 2011, an anticipated receipt date late summer 2011. FOA use U01 cooperative agreement mechanism. Details the planned FOA provided below. Research Initiative Details December 2010, FOAs RFA-NS-11-009, RFA-NS-11-010, RFA-NS-11-008 released a Clinical Coordinating Center CCC), Data Coordinating Center DCC) a group clinical sites, combined form Network Excellence Neuroscience Clinical Trials NEXT). study selected response the planned FOA be conducted through NEXT infrastructure using NEXT clinical sites well ad hoc clinical sites appropriate. Notice encourages investigators expertise insights the area SMA research biomarker discovery begin consider applying this new FOA.  nbsp; addition, collaborative investigations combining expertise neuromuscular disease be encouraged these investigators should also begin considering applying this application. addition scientific discovery, biomarker qualification hoped lead use pivotal clinical trials marketing application. collaboration Food Drug Administration FDA), NIH hold public workshop May 13, 2011 during academics/industry researchers non-government organizations invited present state-of-the-science SMA biomarkers http://www.ninds.nih.gov/news_and_events/proceedings/sma_workshop.htm). workshop include panel discussions. summary the workshop be publicly available the NINDS website. APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: D. Elizabeth McNeil, MD MSc 6001 Executive Boulevard, MSC 9520 Rockville, MD 20852 Phone: 301-496-9135 Fax: 301-480-1080 Email: mcneilde@ninds.nih.gov
Withdrawal of NINDS Participation in PAR-10-266, Support of NIGMS Program Project Grants (P01)
Expiration Date: Saturday, January 1, 2028
NOFO Number: NOT-NS-11-014
Friday, March 25, 2011
Notice Type: NOT
Withdrawal NINDS Participation PAR-10-266, Support NIGMS Program Project Grants P01) Notice Number: NOT-NS-11-014 Key Dates Release Date:   March 25, 2011 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice informs potential applicants that, effective immediately, National Institute Neurological Disorders Stroke NINDS) no longer participate PAR-10-266, Support NIGMS Program Project Grants P01)."  NINDS recently released PAR-11-172, NINDS Program Project Grant P01)," potential applicants should use NINDS-directed P01 submissions.  following Institutes continue participate PAR-10-266: National Institute General Medical Sciences NIGMS) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Diabetes Digestive Kidney Diseases NIDDK) other aspects PAR-10-266 remain unchanged. Inquiries Please direct inquiries to: Alan L. Willard, Ph.D. Deputy Director Extramural Research, NINDS 6001 Executive Blvd, Room 3305 Rockville, MD 20852 couriers) Bethesda, MD 20892-9531 US Mail) Voice: 301-496-9248 Fax: 301-402-4370 Email: AW135Y@NIH.GOV
Clarification, Institutional Clinical and Translational Science Award (U54), RFA-RM-10-020
Expiration Date: Saturday, January 1, 2028
NOFO Number: NOT-RM-11-012
Wednesday, March 23, 2011
Notice Type: NOT
Clarification, Institutional Clinical Translational Science Award U54), RFA-RM-10-020 Notice Number: NOT-RM-11-012 Key Dates Release Date:   March 23, 2011 Issued National Cancer Institute NCI) National Eye Institute NEI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute General Medical Sciences NIGMS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Library Medicine NLM) Fogarty International Center FIC) National Center Complementary Alternative Medicine NCCAM) National Center Research Resources NCRR) Office Behavioral Social Sciences Research OBSSR) Office Dietary Supplements ODS) Office Rare Diseases ORD) Office Research Women’s Health ORWH) Common Fund Roadmap) Purpose Notice issued make 3 amendments the current funding opportunity announcement Clinical Translational Science Awards, RFA-RM-10-020 under following headings: Mentored Research Career Development Component K12) Notice amends current CTSA RFA-RM-10-020 change minimum 9 person-months equivalent 75%) full-time professional effort conducting research scholars select clinical specialty appointments. original version RFA-RM-10-020, Section III 1. Eligible Research Education, Research Training Research Career Development Trainees, Scholars Mentors, reads: KL2 scholars must a research health-professional doctoral degree its equivalent. Candidates must able commit minimum 9 person-months equivalent 75%) conducting research career development research activities associated the program. remaining 3 person-months equivalent 25 %) be divided among research, clinical teaching activities only these activities consistent the proposed goals the KL2 program. is amended read: KL2 scholars must a research health-professional doctoral degree its equivalent. Candidates must able commit minimum 9 person-months equivalent 75%) full-time professional effort conducting research career development research activities associated the program. remaining 3 person-months equivalent 25 % be divided among research, clinical teaching activities only these activities consistent the proposed goals the KL2 program. KL2 scholars appointments certain clinical specialties have less 9 person-months, no less 6 person-months equivalent 50 %) protected time this Program sufficiently justified programmatically approved example, surgical specialties requiring 50 percent direct patient care time maintain surgical skills board eligibility). Review criteria Review Criteria currently include statement: Environment: a program awarding higher degrees clinical research place? the academic scientific environments contribute the probability success establishing maintaining home clinical translational science? there strong training record both institutional faculty levels? Does proposal provide strong evidence the CTSA provide resources would otherwise possible? applicable, there adequate cooperative arrangements between affiliated institutions ensure the CTSA program performs effectively one activity across institutional boundaries? there unique features the scientific environment in available human subject populations collaborative arrangements? infrastructure place indicating likelihood success the proposed C/D/I? is modified read: Environment: a program awarding higher degrees clinical research place? the academic scientific environments contribute the probability success establishing maintaining home clinical translational science? there strong training record both institutional faculty levels? Does proposal provide strong evidence the CTSA provide resources would otherwise possible? the applicants described effective administration governance structure will promote discipline clinical translational science? applications designating multiple PD/PIs, the leadership approach, including designated roles responsibilities, governance organizational structure consistent and justified the aims the CTSA the expertise each the PD/PIs? the governance structure designed ensure both accountability multiple PD/PIs, integration the components the C/D/I a coherent program? the organization the External Advisory Committee within structure the CTSA conducive providing critical, stimulating, thoughtful advice the overall CTSA performance CTSA key functions? applicable, there adequate cooperative arrangements between affiliated institutions ensure the CTSA program performs effectively one activity across institutional boundaries? there unique features the scientific environment in available human subject populations collaborative arrangements? infrastructure place indicating likelihood success the proposed C/D/I? Format the Application Section G Format the Application” currently reads: G. Literature cited a) Bibliography References Cited – Provide bibliography any references cited the Research Plan. reference must include names all authors the same sequence which appear the publication), article journal title, book title, volume number, page numbers, year publication. Include only bibliographic citations. Follow scholarly practices providing citations source materials relied upon preparing any section the application. references should limited relevant current literature. While is a page limitation, is important be concise select only those literature references pertinent the proposed research. b) Progress Report Publication List – Renewal applications list titles complete references all appropriate publications, manuscripts accepted publication, patents, other printed materials have resulted the project since was last reviewed competitively. is amended read: G. Literature cited a) Bibliography References Cited – Provide bibliography any references cited the Research Plan. reference must include names all authors the same sequence which appear the publication), article journal title, book title, volume number, page numbers, year publication. Include only bibliographic citations. Follow scholarly practices providing citations source materials relied upon preparing any section the application. references should limited the relevant current literature. While is a page limitation, is important be concise select only those literature references pertinent the proposed research. b) Progress Report Publication List – Renewal applications list titles complete references all appropriate publications, manuscripts accepted publication, patents, other printed materials have resulted the project since was last reviewed competitively.  Applicable papers directly supported CTSAs subject the Public Access Policy http://publicaccess.nih.gov/determine_applicability.htm criteria), awardees required ensure papers submitted PMCIDs included citations these papers renewal applications. Inquiries Please direct inquiries to: Dr. Anthony Hayward Division Clinical Research Resources, NCRR 6701 Democracy Blvd. Room 906, MCS 4874 Bethesda, MD 20892 Telephone: 301-435-0790 FAX: 301-480-3661 Email: haywarda@mail.nih.gov
Export to:
A maximum of 400 records can be exported.